How I treat hyperleukocytosis in acute myeloid leukemia.

Blood
Christoph Röllig, Gerhard Ehninger

Abstract

Hyperleukocytosis (HL) per se is a laboratory abnormality, commonly defined by a white blood cell count >100,000/µL, caused by leukemic cell proliferation. Not the high blood count itself, but complications such as leukostasis, tumor lysis syndrome, and disseminated intravascular coagulation put the patient at risk and require therapeutic intervention. The risk of complications is higher in acute than in chronic leukemias, and particularly leukostasis occurs more often in acute myeloid leukemia (AML) for several reasons. Only a small proportion of AML patients present with HL, but these patients have a particularly dismal prognosis because of (1) a higher risk of early death resulting from HL complications; and (2) a higher probability of relapse and death in the long run. Whereas initial high blood counts and high lactate dehydrogenase as an indicator for high proliferation are part of prognostic scores guiding risk-adapted consolidation strategies, HL at initial diagnosis must be considered a hematologic emergency and requires rapid action of the admitting physician in order to prevent early death.

References

May 1, 1992·American Journal of Hematology·F A SoaresM C Cardoso
Jan 1, 1988·American Journal of Hematology·G J VenturaM J Keating
Jun 1, 1988·British Journal of Haematology·C S ScottB E Roberts
Sep 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P DutcherP H Wiernik
Dec 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J Bunin, C H Pui
Jan 1, 1983·Medical and Pediatric Oncology·J CuttnerR J Meyer
Oct 1, 1980·The American Journal of Medicine·J CuttnerJ F Holland
Jun 6, 1998·BMJ : British Medical Journal·B J Hunt, K M Jurd
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Pierluigi PorcuMichael Bissell
Aug 26, 2003·Best Practice & Research. Clinical Haematology·Giuseppe Avvisati, Martin S Tallman
May 26, 2007·Seminars in Thrombosis and Hemostasis·William Blum, Pierluigi Porcu
Jul 20, 2007·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ashish DixitRenu Saxena
May 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierMitchell S Cairo
Apr 25, 2009·American Journal of Hematology·Nicola PiccirilloSimona Sica
Jul 29, 2009·Blood·Michael StefanidakisErkki Koivunen
Jun 23, 2010·Journal of Clinical Apheresis·Zbigniew M SzczepiorkowskiUNKNOWN Apheresis Applications Committee of the American Society for Apheresis
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michaël DarmonFrançois Vincent
Aug 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eugenio PiroStefano Molica
Oct 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S Vadhan-RajJ E Romaguera
Mar 1, 2012·Blood Reviews·Chezi GanzelJacob M Rowe
Jun 13, 2012·British Journal of Clinical Pharmacology·John CoutsouvelisAndrew Spencer
Jun 16, 2012·Blood·Tsila ZuckermanJacob M Rowe
Sep 13, 2012·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Kristina Hölig, Rainer Moog
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer

❮ Previous
Next ❯

Citations

Dec 2, 2015·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Paolo Perseghin
Sep 21, 2015·Clinical Lymphoma, Myeloma & Leukemia·Andrew W HahnMike G Martin
Jun 11, 2016·Critical Reviews in Oncology/hematology·Semra Paydas
Oct 19, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Vipin VillgranMichael Boyiadzis
Dec 15, 2016·Expert Review of Hematology·Sabrina GiammarcoLivio Pagano
Jan 7, 2017·Journal of Pediatric Hematology/oncology·Dilek KacarBahattin Tunc
Apr 8, 2017·Mayo Clinic Proceedings·Thorvardur R HalfdanarsonBo E Madsen
Feb 24, 2017·Current Neurology and Neuroscience Reports·Stephanie Berg, Sucha Nand
Nov 18, 2017·Clinical Journal of Oncology Nursing·Lisa M BlackburnMichelle Orovets
Sep 25, 2017·Journal of Clinical Apheresis·Abigail ClineRoni Bollag
Jan 29, 2016·Current Treatment Options in Oncology·Antonio RuggieroRiccardo Riccardi
Mar 23, 2017·American Journal of Respiratory and Critical Care Medicine·Coursen SchneiderAndry Van de Louw
Nov 26, 2019·Blood·Courtney D DiNardo, Andrew H Wei
May 22, 2020·Nature Reviews. Materials·Yongzhi QiuWilbur A Lam
May 11, 2019·BMC Genomics·Sora YoonDougu Nam
May 10, 2016·Nature Reviews. Disease Primers·Asim KhwajaDavid C Linch
Oct 27, 2020·The Analyst·Liangfei FanYubin Ding

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.